Stock Ratings / Health Care / OVID / financials

MPLT (39) CTMX (20) PHAT (46) EOLS (21) ⌘ Pro Terminal →

Ovid Therapeutics Inc. (OVID) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$2.56 +4.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Ovid Therapeutics Inc. (OVID) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $500.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OVID)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How OVID Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $392.0K

FY24

Rev $566.0K

FY25

Rev $7.3M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$7.3M	52%	-80%	-$17.4M	-$38.3M	-28.5%
FY 2024	$566.0K	52%	-80%	-$26.4M	-$56.0M	-45%
FY 2023	$392.0K	52%	-80%	-$52.3M	-$45.8M	-28.5%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OVID)

✓Walkthrough of OVID's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

OVID // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.58%📐 HORIZONTAL RANGE

2026-10-30O $2.51H $2.70L $2.44C $2.56VOL 3.15M

RES: $2.93SUP: $2.08SMA50: $2.54SMA200: $2.36

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OVID Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OVID Butterfly Map → + Track OVID →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on OVID today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OVID. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for OVID today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OVID)

Health Care Rank #637 of 1016 ⚔️ MPLT vs OVID Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OVID vs. MPLT, CTMX, PHAT, EOLS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Ovid Therapeutics Inc. (OVID) ranks #637 by composite RQD confidence (40/100, grade D-) and #452 by equity capitalization ($500.0M). Within this direct 5-issuer industry benchmark cohort, OVID leads on earnings valuation at N/A trailing P/E, while CTMX leads on capital efficiency and profitability with -20.5% ROIC and — gross margin. PHAT currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with OVID at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
OVID ACTIVE Ovid Therapeutics Inc.	D-	40/100	—	—	-28.5%	+4.49%	$500.0M	Benchmark Subject
MPLT MapLight Therapeutics Inc.	D-	39/100	—	—	-32.4%	-3.26%	$500.1M	/mplt-vs-ovid →
CTMX CytomX Therapeutics Inc.	E	20/100	—	—	-20.5%	-2.97%	$499.0M	/ctmx-vs-ovid →
PHAT Phathom Pharmaceuticals Inc.	D	46/100	—	87.1%	-35.0%	-0.95%	$503.2M	/phat-vs-ovid →
EOLS Evolus Inc.	E	21/100	—	66.3%	-35.0%	-1.51%	$496.7M	/eols-vs-ovid →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001636651

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ovid Therapeutics Inc. (OVID) reported GAAP revenue of $7.3M (+1181.3% vs. FY2024 revenue of $566.0K , and +1750.0% cumulative change since FY2023) , GAAP net income of -$17.4M, operating cash flow of -$38.3M, and free cash flow of -$38.3M (+31.6% YoY). On the balance sheet, OVID closed FY2025 with $150.9M in total assets against $0 in total debt (Altman Z-Score: 11.46, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$7.3M	-$17.4M	-$38.3M	-$38.3M	$150.9M	—
FY2024 (FY)	2024-12-31	$566.0K	-$26.4M	-$56.0M	-$56.0M	$92.2M	—
FY2023 (FY)	2023-12-31	$392.0K	-$52.3M	-$45.8M	-$45.8M	—	—

3. OVID Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OVID stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Ovid Therapeutics Inc. (NASDAQ: OVID) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $2.56 (+4.49% 1D, market cap $500.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OVID ranks #637 in composite RQD confidence.

How does OVID compare to MPLT and CTMX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OVID carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.5%. By comparison, MPLT (MapLight Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -32.4%, cap $500.1M) and CTMX (CytomX Therapeutics Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -20.5%, cap $499.0M). Among the 5-stock peer group, OVID leads on earnings multiple (N/A) while CTMX leads on capital efficiency (-20.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OVID?

Per OVID's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001636651), Ovid Therapeutics Inc. generated $7.3M in revenue (+1181.3% YoY), -$17.4M in net income, and -$38.3M in free cash flow against $150.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OVID trading relative to its 50-day, 200-day, and 52-week technical levels?

OVID last traded at $2.56 (+4.49% on volume of 2,043,948 shares), positioning the stock +0.79% above its 50-day simple moving average ($2.54) and +8.47% above its 200-day simple moving average ($2.36). Across its 52-week range of $1.18 to $3.11, OVID sits at the 71.5% percentile with a 14-day RSI of 56.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.24 to $2.88).